MARKET

NGNE

NGNE

Neurogene
NASDAQ
30.41
+0.34
+1.13%
After Hours: 30.59 +0.18 +0.59% 17:00 06/25 EDT
OPEN
30.07
PREV CLOSE
30.07
HIGH
32.00
LOW
29.66
VOLUME
157.64K
TURNOVER
--
52 WEEK HIGH
37.27
52 WEEK LOW
14.65
MARKET CAP
480.54M
P/E (TTM)
-6.6948
1D
5D
1M
3M
1Y
5Y
1D
Neurogene Earns Buy Rating as NGN-401 Shows Superior Efficacy in Rett Syndrome; $60 Price Target Reaffirmed
TipRanks · 3d ago
Weekly Report: what happened at NGNE last week (0615-0619)?
Weekly Report · 3d ago
Weekly Report: what happened at NGNE last week (0608-0612)?
Weekly Report · 06/15 09:01
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
TipRanks · 06/11 11:21
Neurogene Price Target Maintained With a $70.00/Share by HC Wainwright & Co.
Dow Jones · 06/09 10:37
Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
TipRanks · 06/09 10:35
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target
Benzinga · 06/09 10:27
Neurogene: EMBOLDEN Trial Milestone, Competitive Lead Support Reiterated Buy and Unchanged $60 Price Target
TipRanks · 06/08 16:15
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.